🟢 Telix Pharmaceuticals is trading 9% up today after FDA approves Pixclara for glioma imaging

Telix Pharmaceuticals is trading 8.63% up at A$17.75 after the U.S. FDA approved Pixclara on September 14, 2026.

• Pixclara is the first FDA-approved FET-PET imaging drug for glioma and can help distinguish recurrent or progressive tumors from treatment-related changes.
• The company-specific catalyst appears materially stronger than the negative biotech-sector backdrop.
• Trading activity appears elevated, with shares extending the prior session’s gain.